Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2020/05/025466
CTRI/2020/05/025466Completed未知

Measurement of Hydroxychloroquine in blood in asymptomatic healthcare workers on prophylacticregimen for COVID-19 infection - An observational study.

orwich Clinical Services PvtLtd0 sites22 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
22
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • •a. Able to give voluntary informed consent for collection of blood samples and
  • •relevant data for analysis and publication.
  • •b. Either gender, aged above 18 years.

Exclusion Criteria

  • •a. Volunteers who are already on hydroxychloroquine prophylaxis and have less
  • •than 5 weeks remaining out of 8 weeks of hydroxychloroquine prophylaxis for
  • •COVID-19 infection.
  • •b. Volunteers who are already on hydroxychloroquine prophylaxis and develop any adverse drug reaction (ADR) to hydroxychloroquine leading to hospitalization or discontinuation at any time.

Investigators

Sponsor
orwich Clinical Services PvtLtd

Similar Trials

Not yet recruiting
Not Applicable
An observational study on QT interval changes with Hydroxychloroquine used as prophylaxis in COVID exposure risk individuals
CTRI/2020/05/025289P Vamsavardhana Reddy
Not yet recruiting
Not Applicable
Detection of Chloroquine or Hydroxychloroquine Retinopathy by Visual Field 10-2 VS Visual Field 24-2 Combined with Retinal Imaging in Chiang Mai University HospitalPatients taking CQ or HCQ visit ophthalmic OPD of CMU hospital for retinopathy screeningchloroquine, hydroxychloroquine, retinopathy, visual field
TCTR20211222005Chiang Mai University150
Recruiting
Not Applicable
Evaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workers
IRCT20200414047076N1Esfahan University of Medical Sciences160
Not yet recruiting
Phase 3
Efficacy of hydroxychloroquine in graves disease in addition to antithyroid drugs.
CTRI/2023/07/054894IPQA laboratories
Active, not recruiting
Not Applicable
Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01) - Hydroxychloroquine studyHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infection
EUCTR2007-005057-36-GBMedical Research Council